ES2530866T3 - Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF - Google Patents

Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF Download PDF

Info

Publication number
ES2530866T3
ES2530866T3 ES10842718T ES10842718T ES2530866T3 ES 2530866 T3 ES2530866 T3 ES 2530866T3 ES 10842718 T ES10842718 T ES 10842718T ES 10842718 T ES10842718 T ES 10842718T ES 2530866 T3 ES2530866 T3 ES 2530866T3
Authority
ES
Spain
Prior art keywords
proteinuria
patients treated
vegf treatment
early marker
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10842718T
Other languages
English (en)
Spanish (es)
Inventor
Vesna D Garovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Application granted granted Critical
Publication of ES2530866T3 publication Critical patent/ES2530866T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES10842718T 2009-12-21 2010-12-21 Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF Active ES2530866T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28851409P 2009-12-21 2009-12-21
PCT/US2010/061543 WO2011084791A2 (en) 2009-12-21 2010-12-21 Early marker of proteinuria in patients treated with an anti-vegf treatment

Publications (1)

Publication Number Publication Date
ES2530866T3 true ES2530866T3 (es) 2015-03-06

Family

ID=44306097

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10842718T Active ES2530866T3 (es) 2009-12-21 2010-12-21 Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF

Country Status (8)

Country Link
US (4) US20130034861A1 (https=)
EP (1) EP2517014B1 (https=)
JP (1) JP5753541B2 (https=)
AU (1) AU2010339723B2 (https=)
BR (1) BR112012017767A2 (https=)
CA (1) CA2785273A1 (https=)
ES (1) ES2530866T3 (https=)
WO (1) WO2011084791A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
US20130034861A1 (en) 2009-12-21 2013-02-07 Mayo Foundation For Medical Education And Research Early marker of proteinuria in patients treated with an anti-vegf treatment
WO2014104019A1 (ja) * 2012-12-26 2014-07-03 デンカ生研株式会社 尿中ポドサイトの検出方法
WO2021055089A1 (en) * 2019-09-20 2021-03-25 The University Of North Carolina At Chapel Hill Methods of identifying risk of bevacizumab-induced proteinuria and hypertension

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9306053D0 (en) 1993-03-24 1993-05-12 Nycomed Pharma As Method and assay
WO2002037099A1 (en) 2000-10-27 2002-05-10 International Reagents Corporation Method of diagnosing nephropathy
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
WO2003075016A1 (en) 2002-03-07 2003-09-12 Cambridge University Technical Services Limited (Cuts) Scd fingerprints
US20030198959A1 (en) * 2002-03-28 2003-10-23 Kurnit David M. Methods and compositions for analysis of urine samples in the diagnosis and treatment of kidney diseases
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
JP2007532913A (ja) 2004-04-16 2007-11-15 ユニバーシティー オブ マサチューセッツ 細胞内病原体の検出法および定量化法
EP1786477A2 (en) * 2004-08-17 2007-05-23 Prolx Pharmaceuticals Corp. Method of preselection patients for anti-vegf, anti-hif-1 or anti-thioredoxin therapy
US7790463B2 (en) 2006-02-02 2010-09-07 Yale University Methods of determining whether a pregnant woman is at risk of developing preeclampsia
US7820159B2 (en) * 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
WO2008075173A2 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universität Heidelberg Methods for treating podocyte-related disorders
EP2146728A4 (en) 2007-05-21 2010-12-29 Univ Wake Forest Health Sciences PROGENITOR CELLS FROM URINE AND METHODS FOR THEIR USE
US20090068683A1 (en) 2007-06-11 2009-03-12 Mayo Foundation For Medical Education And Research Markers for preeclampsia
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
CN101970486A (zh) * 2007-10-25 2011-02-09 布里斯托尔大学 特异于血管内皮生长因子(vegf)的促血管发生同工型的抗体
WO2010065968A1 (en) 2008-12-05 2010-06-10 Myriad Genetics, Inc. Cancer detection markers
US20120164667A1 (en) 2009-06-10 2012-06-28 Masanori Hara Method for test on diabetic nephropathy
US20130034861A1 (en) 2009-12-21 2013-02-07 Mayo Foundation For Medical Education And Research Early marker of proteinuria in patients treated with an anti-vegf treatment
TWI762890B (zh) 2010-05-12 2022-05-01 開曼群島商英瑞金公司 生物活性腎細胞
AU2013267139B2 (en) 2012-06-01 2018-11-01 Mayo Foundation For Medical Education And Research High-throughput early detection and point-of-care early detection of pregnant women susceptible to developing preeclampsia
WO2014055687A1 (en) 2012-10-05 2014-04-10 Hitachi Chemical Co., Ltd. Urine exosome mrnas and methods of using same to detect diabetic nephropathy
US20170003299A1 (en) 2013-11-27 2017-01-05 Mayo Foundation For Medical Education And Research Detecting podocyte injury in diabetic nephropathy and glomerulonephritis

Also Published As

Publication number Publication date
US10336822B2 (en) 2019-07-02
JP2013515268A (ja) 2013-05-02
WO2011084791A3 (en) 2011-11-24
EP2517014A4 (en) 2013-07-17
EP2517014B1 (en) 2014-11-19
US20160060333A1 (en) 2016-03-03
US20180002416A1 (en) 2018-01-04
US9213038B2 (en) 2015-12-15
US20130296397A1 (en) 2013-11-07
AU2010339723A1 (en) 2012-08-09
US9765137B2 (en) 2017-09-19
AU2010339723B2 (en) 2014-11-06
JP5753541B2 (ja) 2015-07-22
BR112012017767A2 (pt) 2019-09-24
WO2011084791A2 (en) 2011-07-14
US20130034861A1 (en) 2013-02-07
CA2785273A1 (en) 2011-07-14
EP2517014A2 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
AU2018256633A1 (en) Therapy for enteric infections
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
MX2012001716A (es) Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
AR084373A1 (es) Composiciones y metodos para la eliminacion de biopeliculas
ES2572372T3 (es) Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1
WO2010091049A3 (en) Diagnosis and treatment of cancer
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
MX382266B (es) Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama.
EP2464753A4 (en) METHODS AND COMPOSITIONS FOR BIODETECTION
EA202190319A1 (ru) Композиции и способы детектирования биологического загрязнителя
BRPI0906549A2 (pt) Bandagens médicas com válvulas e kits contendo as mesmas.
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
EA200901550A1 (ru) Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
WO2010085542A3 (en) Biomarkers related to age-related macular degeneration (amd)
BRPI0818741A2 (pt) equipamento e método de avaliação da presença de microorganismos no sangue
PH12013502340A1 (en) Biomarkers for hedgehog inhibitor therapy
BRPI0918386A2 (pt) métodos de avaliação de um paciente para incontinência urinária de esforço, sistema de avaliação de um paciente para incontinência urinária de esforço e dispositivo para avaliação de um paciente para incontinência urinária de esforço
EA201690465A1 (ru) Способ оценки эффектов композиции, содержащей микроорганизмы, на кишечную микробиоту
WO2010124101A3 (en) Genetic markers associated with endometriosis and use thereof
ES2530743T3 (es) Método in vitro y kit para el pronóstico o predicción de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor TNFalfa
ES2530866T3 (es) Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF
BRPI1015216A2 (pt) método de tratar ou prevenir uma condição médica em um indivíduo.